These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 8687163)
1. Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: a follow-up study. Ferlazzo G; Magno C; Iemmo R; Rizzo M; Lupo G; Semino C; Bruno S; Melioli G Anticancer Res; 1996; 16(2):979-80. PubMed ID: 8687163 [TBL] [Abstract][Full Text] [Related]
2. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG). Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936 [TBL] [Abstract][Full Text] [Related]
3. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941 [TBL] [Abstract][Full Text] [Related]
5. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer. Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341 [TBL] [Abstract][Full Text] [Related]
6. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer. Okamura T; Tozawa K; Yamada Y; Sakagami H; Ueda K; Kohri K J Urol; 1996 Sep; 156(3):967-71. PubMed ID: 8709375 [TBL] [Abstract][Full Text] [Related]
8. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer. Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer. Elsässer-Beile U; Leiber C; Wetterauer U; Bühler P; Wolf P; Lucht M; Mengs U Anticancer Res; 2005; 25(6C):4733-6. PubMed ID: 16334168 [TBL] [Abstract][Full Text] [Related]
10. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study. Yutkin V; Pode D; Pikarsky E; Mandelboim O J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285 [TBL] [Abstract][Full Text] [Related]
11. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Ojea A; Nogueira JL; Solsona E; Flores N; Gómez JM; Molina JR; Chantada V; Camacho JE; Piñeiro LM; Rodríguez RH; Isorna S; Blas M; Martínez-Piñeiro JA; Madero R; Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161 [TBL] [Abstract][Full Text] [Related]